earticle

논문검색

Anti-VCAM-1 mAb drug development

초록

영어

Vascular cell adhesion molecule-1 (VCAM-1) is a member of the diverse cellular adhesion
molecule family which includes intergrins, selectins, and the immunoglobulin superfamily and is
a critical component of the leukocyte-endothelial adhesion cascade. VCAM-1 is upregulated on
the endothelial under inflammatory conditions including autoimmune inflammatory diseases,
atherosclerosis and organ transplantation rejection.
Transendothelial migration of inflammatory cells is a key step in autoimmune inflammatory
diseases (asthma, rheumatoid arthritis, IBD (inflammatory bowel disease)) and is mediated by
the presence of cell adhesion molecule, including VCAM-1, on the vascular endothelium.
Activated vascular endothelial cell expresses VCAM-1 which can be bound by inflammatory cells
expressing very late antigen-4 (VLA-4), the ligand of VCAM-1. VCAM-1-VLA-4 interaction
plays a vital role in the passage of the inflammatory cell between endothelial cells. Currently,
increasing attention is being paid to VCAM-1-VLA-4 interaction as targets for therapeutic
interventions in inflammatory diseases.
The goal of this study is to develop a novel cross-species specific anti-VCAM-1 therapeutic
antibody for inflammatory disease treatments, which has better advantages for the evaluation of
therapeutic efficacy in preclinical animal models.

저자정보

  • Lee Jung Tae Hanwha Chemical & Research Center Biotech R&D Group

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

      0개의 논문이 장바구니에 담겼습니다.